Cesca: Cesca Therapeutics Announces Receipt Of $2 Million Upfront Distribution Fee

Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary (the "Company"), announced today it has received the $2 million upfront distribution fee pursuant to its global distribution agreement, entered into as of August 30, 2019, for the X-Series® product line.